Life sciences small and medium-sized enterprises (SMEs) need to make high-stakes R&D decisions quickly, from understanding disease biology and validating biomarkers to identifying meaningful patient populations and generating evidence to support product development. Population-scale health data is creating new opportunities to answer these questions, without requiring SMEs to build equivalent research resources themselves. This webinar explores how SMEs can use population-scale health data to support evidence-driven decisions across the drug development lifecycle.
While population-scale health data offers significant potential, scale alone is not enough. The value of a population resource depends on whether it brings together the right populations, biological information, longitudinal health data and research capabilities to answer the evidence question at hand. Increasingly, the opportunity lies in connecting information across people, genetics, biology and time.
The featured panelists will explore how population-scale health data can be applied across the R&D lifecycle, from understanding disease and validating biomarkers to predicting risk, identifying meaningful subgroups and understanding outcomes over time. The session will also examine the questions SMEs should consider when evaluating a population research resource, helping teams begin with the evidence they need rather than simply the data available.
Register for this webinar to learn how SMEs can use population-scale health data to generate stronger evidence and inform research decisions.
